Stockscreener 앱 받기
6.08
2.72%
-0.17
시장 영업 전:
6.07
-0.010
-0.16%
Unicycive Therapeutics Inc 주식(UNCY)의 최신 뉴스
2026-02-12 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Unicycive Therapeutics, Inc. (UNCY) And Encourages Stockholders to Reach Out | NDAQ:UNCY | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Unicycive Therapeutics, Inc. (UNCY) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Investor Mood: Is Open Lending Corporation stock a top performer YTDWatch List & Technical Buy Zone Confirmations - baoquankhu1.vn
Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim’s Emerging Outlook: Biotech Summit - The Manila Times
Bronstein, Gewirtz & Grossman, LLC Encourages Unicycive Therapeutics, Inc. (UNCY) Investors to Inquire about Securities Investigation - ACCESS Newswire
Unicycive Therapeutics Doubles Stock Sale Agreement - MSN
Analysts Offer Insights on Healthcare Companies: Thermo Fisher (TMO), Phibro Animal Health (PAHC) and Unicycive Therapeutics (UNCY) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Protagonist Therapeutics (PTGX) and Unicycive Therapeutics (UNCY) - The Globe and Mail
Unicycive’s Kidney Drug Pipeline Puts A Small Stock On The Clock - Finimize
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Unicycive Therapeutics, Inc. (UNCY) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Unicycive: 'Buy' Rating On NDA Resubmission OLC And Potential Best-In-Class Profile - Seeking Alpha
Take two: Company tries again to win FDA approval for drug for dialysis patients - The Business Journals
Unicycive Therapeutics announces FDA acceptance of oxylanthanum carbonate (OLC) new drug application (NDA) resubmission - marketscreener.com
UPDATEUnicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission - The Manila Times
Unicycive Therapeutics Announces FDA Acceptance Of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission - TradingView
Unicycive granted FDA review for resubmitted marketing application for kidney disease drug - Seeking Alpha
Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission - The Manila Times
FDA sets June 27 action date for Unicycive kidney disease pill - stocktitan.net
FY2030 Earnings Forecast for UNCY Issued By HC Wainwright - Defense World
Unicycive Therapeutics, Inc. (UNCY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - accessnewswire.com
2026-01-27 | Unicycive Therapeutics, Inc. (UNCY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation | NDAQ:UNCY | Press Release - Stockhouse
Analysts Set Expectations for UNCY FY2030 Earnings - MarketBeat
Trading Action: Will Unicycive Therapeutics Inc benefit from current market trends2025 Growth vs Value & Fast Entry and Exit Trade Plans - baoquankhu1.vn
Unicycive Therapeutics, Inc. (UNCY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - accessnewswire.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating Unicycive Therapeutics, Inc. (UNCY) And Encourages Investors to Connect - ACCESS Newswire
2026-01-20 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Unicycive Therapeutics, Inc. (UNCY) And Encourages Investors to Connect | NDAQ:UNCY | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Encourages Unicycive Therapeutics, Inc. (UNCY) Stockholders to Inquire about Securities Investigation - accessnewswire.com
Portfolio Shifts: Is VRAX a top pick in the sectorJuly 2025 Chart Watch & Safe Entry Point Alerts - baoquankhu1.vn
Unicycive Shares Sink After FDA Issues Response Letter on Kidney Drug Filing - MSN
We Might See A Profit From Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Soon - simplywall.st
Unicycive Therapeutics, Inc. (UNCY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Unicycive Therapeutics (NASDAQ:UNCY) Trading 1% HigherShould You Buy? - MarketBeat
Will Unicycive Therapeutics Inc. stock maintain momentum in 2025July 2025 Earnings & Fast Moving Trade Plans - ulpravda.ru
Can Unicycive Therapeutics Inc. stock continue upward trendQuarterly Portfolio Review & Capital Efficiency Focused Ideas - Улправда
Unicycive Therapeutics Inc. (UNCY) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
News | Unicycive Therapeutics leases Mountain View offices - CoStar
How interest rate cuts could boost Unicycive Therapeutics Inc. stockMarket Trend Summary & Consistent Profit Trading Strategies - Улправда
How geopolitical tensions affect Unicycive Therapeutics Inc. stockBull Market Opportunities & Minimal Capital Investment - ulpravda.ru
Unicycive Therapeutics : January 2026 Corporate Presentation - MarketScreener
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Unicycive Therapeutics, Inc. (UNCY) And Encourages Stockholders to Reach Out - ACCESS Newswire
UNCY Stock Price, Forecast & Analysis | UNICYCIVE THERAPEUTICS INC (NASDAQ:UNCY) - Chartmill
What drives Unicycive Therapeutics Inc stock priceTrendline Breakouts & Let Our AI Be Your Trading Assistant - earlytimes.in
Maxim Group Maintains Unicycive Therapeutics(UNCY.US) With Buy Rating, Maintains Target Price $30 - 富途牛牛
Guggenheim reiterates Buy rating on Unicycive stock amid NDA resubmission By Investing.com - Investing.com UK
Unicycive Therapeutics seeks FDA approval — again — for dialysis patients' phosphate treatment - The Business Journals
Unicycive resubmits NDA for hyperphosphatemia asset - Seeking Alpha
Unicycive Therapeutics announces resubmission of new drug application (NDA) for oxylanthanum carbonate (OLC) - marketscreener.com
Unicycive Therapeutics Announces Resubmission of New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) - TradingView — Track All Markets
Unicycive Resubmits New Drug Application for Oxylanthanum Carbonate - MarketScreener
Unicycive resubmits NDA for kidney disease treatment to FDA - Investing.com
Unicycive Therapeutics Resubmits NDA for Oxylanthanum Carbonate to FDA for Chronic Kidney Disease Treatment - Quiver Quantitative
Unicycive Therapeutics Announces Resubmission of New Drug Application (NDA) for Oxylanthanum ... - Caledonian Record
Unicycive Therapeutics Announces Resubmission of New Drug Application for Oxylanthanum Carbonate - marketscreener.com
Companies Like Unicycive Therapeutics (NASDAQ:UNCY) Are In A Position To Invest In Growth - Yahoo Finance
Rally Mode: Can Unicycive Therapeutics Inc stock continue upward trendJuly 2025 Outlook & Fast Moving Stock Trade Plans - moha.gov.vn
Bronstein, Gewirtz & Grossman, LLC Encourages Unicycive Therapeutics, Inc. (UNCY) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Unicycive Therapeutics, Inc. (UNCY) And Encourages Shareholders to Connect - ACCESS Newswire
Why Unicycive Therapeutics Inc. stock is a must watch in 2025Trade Risk Summary & Verified Stock Trade Ideas - Улправда
Is Unicycive Therapeutics Inc. stock a top momentum playLong Setup & Smart Investment Allocation Insights - Улправда
1.24%
0.19%
자본화:
|
볼륨(24시간):